> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Otonomy NDA for Swimmer’s Ear Approved
- URL: https://www.fdaweb.com/otonomy-nda-for-swimmers-ear-approved/
- Published: 2018-03-05T12:00:00.000Z
- Updated: 2026-09-14T23:27:29.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140904

FDA has approved an Otonomy NDA for Otiprio (ciprofloxacin otic suspension) 6% for treating acute otitis externa (swimmer’s ear) caused by *Pseudomonas aeruginosa* and *Staphylococcus aureus* in patients aged six months and older. Otiprio is the first single-dose antibacterial approved by the agency for treating the infection. Topical antibiotics are the current standard of care treatment for acute otitis externa with the typical regimen of ear drops requiring several administrations to the affected ear each day for up to 10 days.